(lp0
S'Idera Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial ... GlobeNewswire  - 14 hours ago CAMBRIDGE, Mass. and EXTON, Pa., March 15, 2017  -- Idera Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel nucleic&nbsp;...Traded Price Fluctuations to Observe: Idera Pharmaceuticals, Inc.  - Is storiesBearish Target Of Idera Pharmaceuticals, Inc.  At $6 - Stock Observer'
p1
aS"Why Shares in Idera Pharmaceuticals, Inc. Dropped 10% Today Motley Fool - Jan 15, 2016 The company's trailing-12-month operating expenses totaled $48.75 million through September, and the company's balance sheet boasted just $95 million exiting Q3, so there's a good chance Idera Pharmaceuticals will be on the hunt for new funding, which&nbsp;..."
p2
aS"Idera Pharmaceuticals' Well-Funded And Growing Pipeline Of Potentially ... Seeking Alpha - Feb 27, 2017 Idera Pharmaceuticals  is a clinical-stage biopharmaceutical company developing novel nucleic acid based therapies for the treatment of certain cancers and rare diseases.Shares of Idera Pharmaceuticals, Inc.  Plunge -4.02% - Energy IndexIdera Pharmaceuticals, Inc.  reported additional data from dose ... - Benchmark Monitor"
p3
aS"How Much Potential Does Idera Pharmaceuticals' Pipeline Really Have? Motley Fool - Oct 9, 2016 However, Idera isn't the only company developing a potential treatment for the disease. Corbus Pharmaceuticals  expects to complete enrollment in the first half of 2017 for its phase 2 study of Resunab in treating dermatomyositis. Resunab&nbsp;..."
p4
aS'Why Idera Pharmaceuticals Inc Stock Is Falling Again Motley Fool - Oct 7, 2016 Investors in Idera Pharmaceuticals  are having another rough day. Shares are down by more than 10% as of 11:45 a.m.'
p5
aS'Why Idera Pharmaceuticals Inc. Is Down Big Today Motley Fool - Oct 6, 2016 Idera produced a net loss of $26.3 million through the first half of the year, leaving it with only $64.1 million in cash as of the end of June.Idera Announces $50M Public Offering  - Investopedia'
p6
aS"Idera Pharmaceuticals,Inc.  Files An 8-K Entry into a Material ... Market Exclusive - Mar 13, 2017 On March 7, 2017, the Board of Directors  of Idera Pharmaceuticals, Inc.  authorized the Company to enter into an Indemnification Agreement with each of the Company's directors and officers (the Indemnification&nbsp;...Idera Pharmaceuticals Inc 's Growing And Robust Pipeline - StockNewsUnionForward Earnings Estimate on Idera Pharmaceuticals, Inc. - Money Flow Index & Trends"
p7
aS'Idera Pharmaceuticals Inc  Reports Additional Phase 1/2 Data In ... Smarter Analyst - Feb 24, 2017 Idera Pharmaceuticals Inc  is reporting additional data from the dose-escalation phase of its ongoing Phase 1/2 clinical trial of intratumoral IMO-2125, an agonist of TLR9 in combination with ipilimumab or pembrolizumab for treatment of&nbsp;...Analyst Activity  Wedbush Reiterates Outperform on Idera Pharmaceuticals ... - Market Exclusive'
p8
aS'Idera Pharmaceuticals: An Intriguing Biotech Buy With Near-Term Catalysts Seeking Alpha - Oct 14, 2016 The company is currently exploring strategic options with former lead treatment IMO-8400, opting instead to focus resources on its immuno-oncology candidate, IMO-2125.'
p9
aS'Idera Pharmaceuticals  Looks Good: Stock Up 13.3% Yahoo Finance - Mar 1, 2017 Idera Pharmaceuticals, Inc. IDRA was a big mover last session, as the company saw its shares rise over 13% on the day.'
p10
a.